

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q92863

Junya TOGUCHIDA

Appln. No.: Based on PCT/JP04/010890

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: January 25, 2006

Examiner: Unknown

For: REMEDY FOR CARTILAGE-RELATED DISEASES

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of the corresponding International Search Report is submitted herewith. The USPTO should receive copies of the references cited in the International Search Report from the International Bureau. Applicant will furnish any missing references upon request.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

IAP5 Rec'd PCT/PTO 25 JAN 2006
10/565831

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: Based on PCT/JP04/010890
Attorney Docket No.: Q92863

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents (International Search Report for PCT/JP04/010890 dated November 16, 2004), together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Mark Boland
Registration No. 32,197

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: January 25, 2006

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
Sheet	1	of	1	Application Number	10/565831 Based on PCT/PTO 10800
				Confirmation Number	Unknown
				Filing Date	January 25, 2006
				First Named Inventor	Junya TOGUCHIDA
				Art Unit	Unknown
				Examiner Name	Unknown
				Attorney Docket Number	Q92863

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,133,230	A	10-17-2000	UNIV. QUEENS KINGSTON

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴			
		WO	03/45371	A1	06-05-2003	PFIZER PROD. INC.
		JP	2001-220357	A	08-14-2001	Pfizer Products Inc.
		WO	98/58911	A2	12-30-1998	PFIZER INC
		JP	2000-507961	A	06-27-2000	PFIZER INC
		JP	2001-220357	A	088-14-2001	Pfizer Products Inc.
		JP	11-193268	A	07-21-1999	Ono Pharmaceutical Co., Ltd.
		WO	02/92064	A2	11-21-2002	MEDICAL RES COUNCIL
		JP	2001-527063	A	12-25-2001	Ono Pharmaceutical Co., Ltd.
		JP	2000-95755	A	04-04-2000	Ono Pharmaceutical Co., Ltd.
		JP	2000-128858	A	05-09-2000	Ono Pharmaceutical Co., Ltd.
		WO	98/34916	A1	08-13-1998	ONO PHARM CO., LTD
		JP	2002-179595	A	06-26-2002	Pfizer Products Inc.
		JP	6-227985	A	08-16-1994	G.D. Searle & Co.
		WO	02/16311	A1	02-28-2002	ONO PHARM CO. LTD.
		WO	02/20462	A1	03-14-2002	ONO PHARM CO. LTD.
		WO	03/16254	A1	02-27-2003	ONO PHARM CO LTD

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			Translation ⁶
		AJ DE-BRUM-FERNANDES, et al., "Characterization of the PGE2 receptor subtype in bovine chondrocytes in culture", Br. J. Pharmacol., 1996, pp. 1597-1604, Vol. 118, No. 7			
		VM PARALKAR, et al., "An EP2 receptor-selective prostaglandin E2 agonist induces bone healing", Proc. Natl. Acad. Sci. USA, May 27, 2003, pp. 6736-6740			
		F DEL TORO JR, et al., "Characterization of prostaglandin E(2) receptors and their role in 24,25-(OH)(2)2(3)-mediated effects on resting zone chondrocytes", J. Cell. Physiol., 2000, pp. 196-208, Vol. 182, No. 2			
		U. SUZUWA, et al., "The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: an analysis using specific agonists for the respective EPs.", Endocrinology, 2000, pp.. 1554-1559, Vol. 141, No. 4			
		E. ROSADO, et al., "Transforming growth factor-β1 regulation of growth zone chondrocytes is mediated by multiple interacting pathways.", Biochim. Biophys. Acta, 2002, pp. 1-15, Vol. 1590, No. 1-3			
		VL SYLVIA, et al., "Transforming growth factor-β1 regulation of resting zone chondrocytes is mediated by two separate but interacting pathways.", Biochim. Biophys. Acta, 2000, pp/ 311-324, Vol. 1496, No. 2-3			
		VL SYLVIA, et al., "Characterization of PGE ₂ receptors (EP) and their role as mediators of 1α,25-(OH) ₂ D ₃ effects on growth zone chondrocytes.", J. Steroid Biochem. Mol. Biol., 2001, pp. 261-274, Vol. 78, No.3			
		JM MCCOY, et al. "The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis.", J. Clin. Invest., 2002, pp. 651-658, Vol. 110, No. 5			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.